Healthy Volunteers
Conditions
Brief summary
This is a Phase 1, multi-center, randomized, double-blinded, placebo-controlled single (SAD) and multiple ascending (MAD) ascending dose study to assess the safety, tolerability, and pharmacokinetics (PK) of IGM-6268 administered intranasally and intraorally in healthy volunteers. IGM-6268 or placebo will be administered by intranasal + intraoral spray using a Teleflex Mucosal Atomization Device Nasal™ Intranasal Mucosal Atomization Device once (SAD), or once or twice each day for 5 days (MAD).
Detailed description
IGM-6268 is an engineered Immunoglobulin M (IgM) antibody that specifically targets the receptor binding domain (RBD) of the SARS-CoV-2 spike protein. This humanized pentameric IgM antibody has 10 binding sites to the spike protein and a J-chain to enable the formation of IgM pentamers. IGM-6268 is being developed as a treatment for or prophylaxis of symptoms associated with mild to moderate COVID-19. The primary mechanism of action of IGM-6268 is to block the binding of the SARS-CoV-2 RBD on the spike protein to human angiotensin converting enzyme 2 (hACE2), the cellular receptor for SARS-CoV-2. By blocking this binding, IGM 6268 neutralizes the infectivity of the virus.
Interventions
DRUGIGM-6268
Active comparator
DRUGPlacebo
Placebo comparator
Sponsors
IGM Biosciences, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Investigator)
Masking description
Cohorts 1-6 will receive IGM-6268 or placebo. Subjects and Investigators will be blinded.
Intervention model description
Subjects will be randomized to receive intranasal and intraoral administration of IGM-6268 or placebo at the assigned doses. Cohorts will be enrolled sequentially.
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Is male or non-pregnant female adult ≥ 18 and ≤ 55 years of age * Has a body mass index (BMI) \< 35 kg/m2. * Is healthy as determined by medical history, physical examination, 12-lead electrocardiogram, laboratory assessments, and vital signs at screening. * For women of childbearing potential or men, agreement to use at least one highly effective form of non-hormonal contraception or one highly effective form and one effective form of non-hormonal contraception through the course of study treatment and for 3 months after the last dose of IGM-6268. * Agrees to the collection of blood, urine, saliva, and nasopharyngeal samples, per protocol.
Exclusion criteria
* Receipt of any COVID-19 vaccine or contemplating receipt of any COVID-19 vaccine (or participating in a COVID-19 vaccine trial) during this study and follow-up periods (approximately 65 days from enrollment). Subjects are permitted to withdraw at any time if they decide to receive the vaccine * History of prior positive SARS-CoV-2 diagnostic test (antigen or NAAT), or positive SARS-CoV-2 serology test, at any time before enrollment. * Confirmed or suspected pulmonary or systemic bacterial infection. * Current or planned participation in any interventional clinical trial during the study and follow-up periods. * History of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. * Uncontrolled human immunodeficiency virus (HIV) infection. * Nasal polyps (history or physical exam) or any structural abnormality of nose that, in the opinion of the investigator, could compromise administration or receipt of study drug (e.g., nasal septal deviation). * History of reactive airway disease or hypersensitivity to any component of study drug or placebo. * Use of any nasally-administered drug between 5 days prior to study enrollment and 2 days after receipt of last dose administered.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety & tolerability of IGM-6268 by assessing the number, severity, and type of adverse events per CTCAE 5.0 | Through 60 days following receipt of final dose |
Secondary
| Measure | Time frame |
|---|---|
| IGM-6268 in serum | Predose through Day 3 (SAD) or Day 6 (MAD) |
| Incidence of anti-IGM-6268 antibodies in serum | Prior to dosing and at Day 28 following receipt of initial dose |
Countries
United States
Outcome results
None listed